Therapeutic Strategies Aimed at Improving Neuroplasticity in Alzheimer Disease

Abstract

Alzheimer disease (AD) is the most prevalent form of dementia among elderly people. Owing to its varied and multicausal etiopathology, intervention strategies have been highly diverse. Despite ongoing advances in the field, efficient therapies to mitigate AD symptoms or delay their progression are still of limited scope. Neuroplasticity, in broad terms the ability of the brain to modify its structure in response to external stimulation or damage, has received growing attention as a possible therapeutic target, since the disruption of plastic mechanisms in the brain appear to correlate with various forms of cognitive impairment present in AD patients. Several pre-clinical and clinical studies have attempted to enhance neuroplasticity via different mechanisms, for example, regulating glucose or lipid metabolism, targeting the activity of neurotransmitter systems, or addressing neuroinflammation. In this review, we first describe several structural and functional aspects of neuroplasticity. We then focus on the current status of pharmacological approaches to AD stemming from clinical trials targeting neuroplastic mechanisms in AD patients. This is followed by an analysis of analogous pharmacological interventions in animal models, according to their mechanisms of action.

Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough

“…The administration of Entacapone has been observed to result in an extension of retention latencies, suggesting its potential efficacy in enhancing memory performance in passive avoidance tests (Baweja et al, 2023). The study revealed that the COMT inhibitor demonstrated favourable effects on prepulse inhibition and executive function, which were contingent on the individual's genotype (Colavitta & Barrantes, 2023). Comparable outcomes were observed in the human specimens (Khor et al, 2023).…”

Anti-Cholinergic Effects of the Phenolic Extract from the Astragalus crenatus Plant: A Computational and Network Pharmacology Study

“…Therefore, the use of the bioactive inhibitors acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) is considered to be one of the most effective therapies for the management of neurodegenerative disorders. Reduced symptoms of AD may be achieved by blocking these two enzymes, which improves coordination between the cholinergic system and the nerve terminals [ 4 ]. A variety of synthetic drugs, including galanthamine, donepezil, tacrine, memantine, caproctamine, and rivastigmine, have been applied to manage moderate to severe AD [ 5 ].…”

“…A variety of synthetic drugs, including galanthamine, donepezil, tacrine, memantine, caproctamine, and rivastigmine, have been applied to manage moderate to severe AD [ 5 ]. Nevertheless, longer-term trials have demonstrated a deterioration in clinical effectiveness, either due to a loss of pharmacological effectiveness or the inexorable advancement of the disease [ 4 ]. In addition, these medications exhibited many adverse effects, including gastrointestinal distress, nausea, vertigo, hepatotoxicity, diarrhea, and vomiting.…”

Abordagens Terapêuticas no Tratamento da Doença de Alzheimer: uma revisão abrangente

“…Além disso, estratégias terapêuticas voltadas para o aprimoramento da neuroplasticidade têm se destacado como uma abordagem promissora no tratamento da doença de Alzheimer (DA). O estudo conduzido por María F. DA, promovendo uma nova perspectiva na busca por soluções terapêuticas inovadoras (Colavitta et al, 2023).…”